Saisei Ventures
Martin Ostrowski is currently the Chief Technology Officer at Kenai Therapeutics, a biotechnology company focused on neuron replacement therapies. Prior to this role, Martin was the President & COO at Dianomi Therapeutics and the Founder & Chief Technology Officer at Vascugen. With a background in biochemistry and bioengineering, Martin has also held roles at companies like Chelon Therapeutics and CELLSCRIPT. Additionally, Martin has experience in business development, intellectual property, and as an intellectual property attorney.
This person is not in any teams
Saisei Ventures
Saisei Ventures is a leading venture capital firm focused on growing and harnessing the Japanese biotech ecosystem; a region rich in opportunities and potential. We create ventures that start from bold ideas and empower dynamic entrepreneurs by filling in technical, operational, or financial gaps. Our approach combines Western expertise and Japanese innovation to build globally competitive companies that will have the greatest impact on patient lives.